139 related articles for article (PubMed ID: 38824414)
1. Lost in the plot: missing visual elements in Kaplan-Meier plots of phase III oncology trials.
Sherry AD; Msaouel P; Kouzy R; Abi Jaoude J; Lin TA; Taniguchi CM; Fuller CD; Minsky B; Ludmir EB
Oncologist; 2024 Jun; ():. PubMed ID: 38824414
[TBL] [Abstract][Full Text] [Related]
2. Differential Treatment Effects of Subgroup Analyses in Phase 3 Oncology Trials From 2004 to 2020.
Sherry AD; Hahn AW; McCaw ZR; Abi Jaoude J; Kouzy R; Lin TA; Minsky B; Fuller CD; Meirson T; Msaouel P; Ludmir EB
JAMA Netw Open; 2024 Mar; 7(3):e243379. PubMed ID: 38546648
[TBL] [Abstract][Full Text] [Related]
3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
4. Censored patients in Kaplan-Meier plots of cancer drugs: An empirical analysis of data sharing.
Rosen K; Prasad V; Chen EY
Eur J Cancer; 2020 Dec; 141():152-161. PubMed ID: 33160265
[TBL] [Abstract][Full Text] [Related]
5. A Comparison of Statistical Analysis Between "Real" Patients Reported in Kaplan-Meier Curves and "Reconstructed" Patients Estimated Through the IPDfromKM Method: Analysis of Eight Trials Evaluating Catheter Ablation of Ventricular Tachycardia.
Messori A; Fadda V; Romeo MR; Veneziano S; Trippoli S
Cureus; 2023 Oct; 15(10):e47891. PubMed ID: 37905162
[TBL] [Abstract][Full Text] [Related]
6. Informative censoring of surrogate end-point data in phase 3 oncology trials.
Gilboa S; Pras Y; Mataraso A; Bomze D; Markel G; Meirson T
Eur J Cancer; 2021 Aug; 153():190-202. PubMed ID: 34186504
[TBL] [Abstract][Full Text] [Related]
7. Empirical power comparison of statistical tests in contemporary phase III randomized controlled trials with time-to-event outcomes in oncology.
Horiguchi M; Hassett MJ; Uno H
Clin Trials; 2020 Dec; 17(6):597-606. PubMed ID: 32933339
[TBL] [Abstract][Full Text] [Related]
8. Proposals on Kaplan-Meier plots in medical research and a survey of stakeholder views: KMunicate.
Morris TP; Jarvis CI; Cragg W; Phillips PPJ; Choodari-Oskooei B; Sydes MR
BMJ Open; 2019 Sep; 9(9):e030215. PubMed ID: 31575572
[TBL] [Abstract][Full Text] [Related]
9. Discrepancies in endpoints between clinical trial protocols and clinical trial registration in randomized trials in oncology.
Serpas VJ; Raghav KP; Halperin DM; Yao J; Overman MJ
BMC Med Res Methodol; 2018 Dec; 18(1):169. PubMed ID: 30541475
[TBL] [Abstract][Full Text] [Related]
10. The maraca plot: A novel visualization of hierarchical composite endpoints.
Karpefors M; Lindholm D; Gasparyan SB
Clin Trials; 2023 Feb; 20(1):84-88. PubMed ID: 36373800
[TBL] [Abstract][Full Text] [Related]
11. Visualizing length of survival in time-to-event studies: a complement to Kaplan-Meier plots.
Royston P; Parmar MK; Altman DG
J Natl Cancer Inst; 2008 Jan; 100(2):92-7. PubMed ID: 18182621
[TBL] [Abstract][Full Text] [Related]
12. Deviation from the Proportional Hazards Assumption in Randomized Phase 3 Clinical Trials in Oncology: Prevalence, Associated Factors, and Implications.
Rahman R; Fell G; Ventz S; Arfé A; Vanderbeek AM; Trippa L; Alexander BM
Clin Cancer Res; 2019 Nov; 25(21):6339-6345. PubMed ID: 31345838
[TBL] [Abstract][Full Text] [Related]
13. Use of endpoints in multiple myeloma randomized controlled trials over the last 15 years: A systematic review.
Mohyuddin GR; Koehn K; Abdallah AO; W Sborov D; Rajkumar SV; Kumar S; McClune B
Am J Hematol; 2021 Jun; 96(6):690-697. PubMed ID: 33735453
[TBL] [Abstract][Full Text] [Related]
14. The influence of industry sponsorship on the reporting of subgroup analyses within phase III randomised controlled trials in gastrointestinal oncology.
Barton S; Peckitt C; Sclafani F; Cunningham D; Chau I
Eur J Cancer; 2015 Dec; 51(18):2732-9. PubMed ID: 26608121
[TBL] [Abstract][Full Text] [Related]
15. The use of validated and nonvalidated surrogate endpoints in two European Medicines Agency expedited approval pathways: A cross-sectional study of products authorised 2011-2018.
Schuster Bruce C; Brhlikova P; Heath J; McGettigan P
PLoS Med; 2019 Sep; 16(9):e1002873. PubMed ID: 31504034
[TBL] [Abstract][Full Text] [Related]
16. [Surrogate endpoints].
Hill C
Bull Cancer; 1999; 86(7-8):622-4. PubMed ID: 10477379
[TBL] [Abstract][Full Text] [Related]
17. Reporting of loss to follow-up information in randomised controlled trials with time-to-event outcomes: a literature survey.
Vervölgyi E; Kromp M; Skipka G; Bender R; Kaiser T
BMC Med Res Methodol; 2011 Sep; 11():130. PubMed ID: 21936924
[TBL] [Abstract][Full Text] [Related]
18. Self-reported conflicts of interest of authors, trial sponsorship, and the interpretation of editorials and related phase III trials in oncology.
Bariani GM; de Celis Ferrari AC; Hoff PM; Krzyzanowska MK; Riechelmann RP
J Clin Oncol; 2013 Jun; 31(18):2289-95. PubMed ID: 23630201
[TBL] [Abstract][Full Text] [Related]
19. Estimating hazard ratios from published Kaplan-Meier survival curves: A methods validation study.
Saluja R; Cheng S; Delos Santos KA; Chan KKW
Res Synth Methods; 2019 Sep; 10(3):465-475. PubMed ID: 31134735
[TBL] [Abstract][Full Text] [Related]
20. Heart Failure with Preserved Ejection Fraction Trials Have Heterogeneous Control Groups: a Comparison of Kaplan-Meier Curves.
Luo H; Zhang C; Wang J; Zhu J; Jia X
Cardiovasc Drugs Ther; 2018 Dec; 32(6):577-580. PubMed ID: 30187346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
